Loading…
Is there a place for magnesium in the treatment of acute myocardial infarction?
Infusions of solutions of magnesium sulfate for patients with acute myocardial infarction were shown by a meta-analysis of seven small studies and a larger study of 2316 patients (LIMIT-2) to have clinical efficacy. However, the ISIS-4 study of 58,050 patients found no improvement in short-term mort...
Saved in:
Published in: | The American heart journal 1996-08, Vol.132 (2), p.471-477 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c389t-8e08beb5898630f25280432ead22693311bfcb263b03bec651198f171b9384d33 |
---|---|
cites | cdi_FETCH-LOGICAL-c389t-8e08beb5898630f25280432ead22693311bfcb263b03bec651198f171b9384d33 |
container_end_page | 477 |
container_issue | 2 |
container_start_page | 471 |
container_title | The American heart journal |
container_volume | 132 |
creator | Seelig, Mildred S. Elin, Ronald J. |
description | Infusions of solutions of magnesium sulfate for patients with acute myocardial infarction were shown by a meta-analysis of seven small studies and a larger study of 2316 patients (LIMIT-2) to have clinical efficacy. However, the ISIS-4 study of 58,050 patients found no improvement in short-term mortality rates with magnesium therapy in patients with acute myocardial infarction. In this article we explore the following four differences between the ISIS-4 study and the earlier studies: (1) Time of initiation of magnesium treatment after acute myocardial infarction and thrombolytic therapy; (2) dosage of magnesium in the first 24 hours after acute myocardial infarction; (3) duration of magnesium infusion after acute myocardial infarction; and (4) differences in patient risks in control and treatment groups. These four differences may explain the different outcomes among these studies and indicate the type of additional studies that are needed to define the clinical utility of magnesium infusion in the treatment of patients with acute myocardial infarction. |
doi_str_mv | 10.1016/S0002-8703(96)90338-5 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78199011</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002870396903385</els_id><sourcerecordid>78199011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-8e08beb5898630f25280432ead22693311bfcb263b03bec651198f171b9384d33</originalsourceid><addsrcrecordid>eNqFkMtKAzEUhoMotVYfoZCFiC5Gk8lMJlkVKV4KhS7UdchkTjQyl5pkhL690wvdujoc_u9c-BCaUnJPCeUPb4SQNBEFYbeS30nCmEjyEzSmRBYJL7LsFI2PyDm6COF7aHkq-AiNBJfZ0IzRahFw_AIPWON1rQ1g23nc6M8Wgusb7NptjKMHHRtoI-4s1qaPgJtNZ7SvnK4HyGpvouva2SU6s7oOcHWoE_Tx_PQ-f02Wq5fF_HGZGCZkTAQQUUKZCyk4IzbNU0EyloKu0pRLxigtrSlTzkrCSjA8p1QKSwtaSiayirEJutnvXfvup4cQVeOCgbrWLXR9UIWgUhJKBzDfg8Z3IXiwau1do_1GUaK2ItVOpNpaUpKrnUiVD3PTw4G-bKA6Th3MDfn1IdfB6Np63RoXjhijIs9EMWCzPQaDjF8HXgXjoDVQOQ8mqqpz_zzyB394jdY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78199011</pqid></control><display><type>article</type><title>Is there a place for magnesium in the treatment of acute myocardial infarction?</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Seelig, Mildred S. ; Elin, Ronald J.</creator><creatorcontrib>Seelig, Mildred S. ; Elin, Ronald J.</creatorcontrib><description>Infusions of solutions of magnesium sulfate for patients with acute myocardial infarction were shown by a meta-analysis of seven small studies and a larger study of 2316 patients (LIMIT-2) to have clinical efficacy. However, the ISIS-4 study of 58,050 patients found no improvement in short-term mortality rates with magnesium therapy in patients with acute myocardial infarction. In this article we explore the following four differences between the ISIS-4 study and the earlier studies: (1) Time of initiation of magnesium treatment after acute myocardial infarction and thrombolytic therapy; (2) dosage of magnesium in the first 24 hours after acute myocardial infarction; (3) duration of magnesium infusion after acute myocardial infarction; and (4) differences in patient risks in control and treatment groups. These four differences may explain the different outcomes among these studies and indicate the type of additional studies that are needed to define the clinical utility of magnesium infusion in the treatment of patients with acute myocardial infarction.</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/S0002-8703(96)90338-5</identifier><identifier>PMID: 8694006</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Biological and medical sciences ; Calcium Channel Blockers - therapeutic use ; Cardiovascular system ; Clinical Trials as Topic ; Humans ; Infusions, Intravenous ; Magnesium Sulfate - therapeutic use ; Medical sciences ; Miscellaneous ; Myocardial Infarction - drug therapy ; Myocardial Infarction - mortality ; Myocardial Reperfusion ; Pharmacology. Drug treatments ; Thrombolytic Therapy ; Treatment Outcome</subject><ispartof>The American heart journal, 1996-08, Vol.132 (2), p.471-477</ispartof><rights>1996</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-8e08beb5898630f25280432ead22693311bfcb263b03bec651198f171b9384d33</citedby><cites>FETCH-LOGICAL-c389t-8e08beb5898630f25280432ead22693311bfcb263b03bec651198f171b9384d33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3185487$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8694006$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seelig, Mildred S.</creatorcontrib><creatorcontrib>Elin, Ronald J.</creatorcontrib><title>Is there a place for magnesium in the treatment of acute myocardial infarction?</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Infusions of solutions of magnesium sulfate for patients with acute myocardial infarction were shown by a meta-analysis of seven small studies and a larger study of 2316 patients (LIMIT-2) to have clinical efficacy. However, the ISIS-4 study of 58,050 patients found no improvement in short-term mortality rates with magnesium therapy in patients with acute myocardial infarction. In this article we explore the following four differences between the ISIS-4 study and the earlier studies: (1) Time of initiation of magnesium treatment after acute myocardial infarction and thrombolytic therapy; (2) dosage of magnesium in the first 24 hours after acute myocardial infarction; (3) duration of magnesium infusion after acute myocardial infarction; and (4) differences in patient risks in control and treatment groups. These four differences may explain the different outcomes among these studies and indicate the type of additional studies that are needed to define the clinical utility of magnesium infusion in the treatment of patients with acute myocardial infarction.</description><subject>Biological and medical sciences</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Cardiovascular system</subject><subject>Clinical Trials as Topic</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Magnesium Sulfate - therapeutic use</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - mortality</subject><subject>Myocardial Reperfusion</subject><subject>Pharmacology. Drug treatments</subject><subject>Thrombolytic Therapy</subject><subject>Treatment Outcome</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><recordid>eNqFkMtKAzEUhoMotVYfoZCFiC5Gk8lMJlkVKV4KhS7UdchkTjQyl5pkhL690wvdujoc_u9c-BCaUnJPCeUPb4SQNBEFYbeS30nCmEjyEzSmRBYJL7LsFI2PyDm6COF7aHkq-AiNBJfZ0IzRahFw_AIPWON1rQ1g23nc6M8Wgusb7NptjKMHHRtoI-4s1qaPgJtNZ7SvnK4HyGpvouva2SU6s7oOcHWoE_Tx_PQ-f02Wq5fF_HGZGCZkTAQQUUKZCyk4IzbNU0EyloKu0pRLxigtrSlTzkrCSjA8p1QKSwtaSiayirEJutnvXfvup4cQVeOCgbrWLXR9UIWgUhJKBzDfg8Z3IXiwau1do_1GUaK2ItVOpNpaUpKrnUiVD3PTw4G-bKA6Th3MDfn1IdfB6Np63RoXjhijIs9EMWCzPQaDjF8HXgXjoDVQOQ8mqqpz_zzyB394jdY</recordid><startdate>19960801</startdate><enddate>19960801</enddate><creator>Seelig, Mildred S.</creator><creator>Elin, Ronald J.</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960801</creationdate><title>Is there a place for magnesium in the treatment of acute myocardial infarction?</title><author>Seelig, Mildred S. ; Elin, Ronald J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-8e08beb5898630f25280432ead22693311bfcb263b03bec651198f171b9384d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Biological and medical sciences</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Cardiovascular system</topic><topic>Clinical Trials as Topic</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Magnesium Sulfate - therapeutic use</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - mortality</topic><topic>Myocardial Reperfusion</topic><topic>Pharmacology. Drug treatments</topic><topic>Thrombolytic Therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seelig, Mildred S.</creatorcontrib><creatorcontrib>Elin, Ronald J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seelig, Mildred S.</au><au>Elin, Ronald J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is there a place for magnesium in the treatment of acute myocardial infarction?</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>1996-08-01</date><risdate>1996</risdate><volume>132</volume><issue>2</issue><spage>471</spage><epage>477</epage><pages>471-477</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>Infusions of solutions of magnesium sulfate for patients with acute myocardial infarction were shown by a meta-analysis of seven small studies and a larger study of 2316 patients (LIMIT-2) to have clinical efficacy. However, the ISIS-4 study of 58,050 patients found no improvement in short-term mortality rates with magnesium therapy in patients with acute myocardial infarction. In this article we explore the following four differences between the ISIS-4 study and the earlier studies: (1) Time of initiation of magnesium treatment after acute myocardial infarction and thrombolytic therapy; (2) dosage of magnesium in the first 24 hours after acute myocardial infarction; (3) duration of magnesium infusion after acute myocardial infarction; and (4) differences in patient risks in control and treatment groups. These four differences may explain the different outcomes among these studies and indicate the type of additional studies that are needed to define the clinical utility of magnesium infusion in the treatment of patients with acute myocardial infarction.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>8694006</pmid><doi>10.1016/S0002-8703(96)90338-5</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-8703 |
ispartof | The American heart journal, 1996-08, Vol.132 (2), p.471-477 |
issn | 0002-8703 1097-6744 |
language | eng |
recordid | cdi_proquest_miscellaneous_78199011 |
source | Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list) |
subjects | Biological and medical sciences Calcium Channel Blockers - therapeutic use Cardiovascular system Clinical Trials as Topic Humans Infusions, Intravenous Magnesium Sulfate - therapeutic use Medical sciences Miscellaneous Myocardial Infarction - drug therapy Myocardial Infarction - mortality Myocardial Reperfusion Pharmacology. Drug treatments Thrombolytic Therapy Treatment Outcome |
title | Is there a place for magnesium in the treatment of acute myocardial infarction? |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T11%3A19%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20there%20a%20place%20for%20magnesium%20in%20the%20treatment%20of%20acute%20myocardial%20infarction?&rft.jtitle=The%20American%20heart%20journal&rft.au=Seelig,%20Mildred%20S.&rft.date=1996-08-01&rft.volume=132&rft.issue=2&rft.spage=471&rft.epage=477&rft.pages=471-477&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1016/S0002-8703(96)90338-5&rft_dat=%3Cproquest_cross%3E78199011%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c389t-8e08beb5898630f25280432ead22693311bfcb263b03bec651198f171b9384d33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=78199011&rft_id=info:pmid/8694006&rfr_iscdi=true |